Cetera Advisors’s UroGen Pharma URGN Stock Holding History

Cetera Advisors’s Portfolio URGN Stock Details URGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-7,950	Closed	-$208K	–	998
2020 Q2	$208K	Buy	+7,950	New	+$194K	0.01%	834

Other funds holding URGN

MMH

Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

WCM

Wildcat Capital Management New York $106M AUM 0.1% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Phoenix Financial Givatayim, Israel $10.5B AUM 49.21% 1-Year Est. Return

MIFH

Migdal Insurance & Financial Holdings Petach Tikva, Israel $11.5B AUM 52.5% 1-Year Est. Return

Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Cetera Advisors's URGN Position: Q3 2020 in Review

Cetera Advisors sold out of UroGen Pharma (URGN) in Q3 2020, closing a stake of 7,950 shares — an estimated $208K sold.

Cetera Advisors first reported a position in URGN in Q2 2020 and held it in 1 quarter. The position peaked at $208K in Q2 2020. 80 funds tracked by Wall St. Rank hold URGN as of Q3 2020.

Cetera Advisors reported no remaining UroGen Pharma position as of Q3 2020 after selling out during the quarter.
Cetera Advisors sold 7,950 UroGen Pharma shares in Q3 2020, an estimated $208K.
Cetera Advisors first reported a position in UroGen Pharma in Q2 2020 and held it in 1 quarter.
Cetera Advisors's UroGen Pharma position peaked at $208K in Q2 2020.
80 funds tracked by Wall St. Rank held UroGen Pharma as of Q3 2020.

Based on Cetera Advisors's 13F filing for Q3 2020, filed 13 Nov 2020.